Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,446 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard response Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study

NCT04482036
View directory record Official record
Conditions
Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
Interventions
Mobile Phone Application Assessments, Standard Assessments
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

NCT02383498
View directory record Official record
Conditions
Chordoma
Interventions
Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
Other · Biological · Radiation + 1 more
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

NCT00640614
View directory record Official record
Conditions
Contact Dermatitis
Interventions
T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 25, 2026, 5:19 AM EDT
Recruiting Not applicable Interventional

Sacral Neuromodulation for Chronic Pelvic Pain

NCT06150599
View directory record Official record
Conditions
Chronic Pelvic Pain Syndrome
Interventions
Sacral neuromodulation
Device
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 5:19 AM EDT
Active, not recruiting Not applicable Interventional

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

NCT06311045
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
N-acetylcysteine (NAC), Placebo, Positive Airway Pressure (PAP) Therapy
Dietary Supplement · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 5:19 AM EDT
Active, not recruiting No phase listed Observational

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05981131
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
N803 plus Bacillus Calmette-Guerin (BCG)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 25, 2026, 5:19 AM EDT
Not listed Not applicable Interventional

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

NCT02577302
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Device
Lead sponsor
Uro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 25, 2026, 5:19 AM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 5:19 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

NCT03972683
View directory record Official record
Conditions
Vasoconstriction, Vasodilation
Interventions
Handgrip Exercise Training, Acetylcholine, Adenosine Triphosphate, Atropine, Phenylephrine, Sodium Nitroprusside
Other · Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 25, 2026, 5:19 AM EDT
Terminated No phase listed Observational

Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt

NCT03043339
View directory record Official record
Conditions
Renal Transplant
Interventions
Stool Specimen Collection, Anal Swab Sampling, Short Diet Assessment (SDA), NHANES Dietary Screener Questionnaire (DSQ)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms and Treatment Response of Aggressive Periodontitis in Children

NCT01330719
View directory record Official record
Conditions
Aggressive Periodontitis
Interventions
Diseased periodontal treatment, Conventional periodontal treatment
Procedure
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 90 Years
Enrollment
514 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2022
U.S. locations
10
States / cities
Brooker, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men (YMSM)

NCT03414372
View directory record Official record
Conditions
Hiv, HIV/AIDS, Disclosure
Interventions
Tough Talks Online, Tough Talks Clinic, Standard of Care
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 29 Years · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

NCT03817853
View directory record Official record
Conditions
Advanced Follicular Lymphoma
Interventions
Obinutuzumab, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Boulder, Colorado • Bethesda, Maryland • Florham Park, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 25, 2026, 5:19 AM EDT
Recruiting Not applicable Interventional

Enhancing the Effectiveness of Home-delivery Based Produce Prescription Program Implementation Strategies

NCT06114199
View directory record Official record
Conditions
Nutritional Deficiency in Pregnancy
Interventions
Produce Prescription Program (PPRx) Standard, Smartphone App
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone

NCT03375567
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Guided Lesion Biopsies, Standard Lesion Biopsies
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 25, 2026, 5:19 AM EDT
Terminated Not applicable Interventional

Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure

NCT02783716
View directory record Official record
Conditions
Heart Failure
Interventions
Subcutaneous adipose tissue collection, Peripheral arterial tonometry (PAT)
Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 25, 2026, 5:19 AM EDT
Completed No phase listed Observational

DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics

NCT04877652
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Standard of care
Other
Lead sponsor
Revamp Medical Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

The HOPE Trial and the SMART Study

NCT03022032
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Fitbit Zip, HOPE App, Standard of Care, Fitbit Charge 2, SMART Study Intervention
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 25, 2026, 5:19 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery

NCT06683378
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reparative Autologous peripheral nerve tissue
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
45 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Early Phase 1 Interventional

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02405078
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

NCT01336933
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
Interventions
prednisone, cyclophosphamide, etoposide, Vincristine, pralatrexate, laboratory biomarker analysis, comparative genomic hybridization, gene expression analysis, nucleic acid sequencing, mutation analysis, immunohistochemistry staining method, microarray analysis, RNA analysis
Drug · Other · Genetic
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Stanford, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 25, 2026, 5:19 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Livionex on Reducing Plaque Accumulation and Improving Oral Health in Children

NCT04368533
View directory record Official record
Conditions
Plaque, Dental, Caries, Dental, Oral Hygiene
Interventions
Livionex Dental Gel, A standard children's toothpaste containing 1500 ppm fluoride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
9 Months to 12 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 25, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 25, 2026, 5:19 AM EDT